Mesoblast (NASDAQ:MESO) Stock Breaks Above 200 Day Moving Average - Here's Why

Key Points

• Mesoblast shares moved above their 200-day moving average, reaching $15.82 and last trading at $15.67 on heavy volume.
• Investor sentiment improved after the company reported 44% year-over-year revenue growth, driven by Ryoncil sales, alongside a sharp reduction in cash burn that may extend its cash runway.
• Analyst sentiment remains mixed: two analysts rate the stock Buy and one rates it Sell, producing a consensus Hold rating with a $39 price target; however, the company remains exposed to execution, regulatory and commercialization risks.

Mesoblast Limited (NASDAQ:MESO - Get Free Report) passed above its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $15.45 and traded as high as $15.82. Mesoblast shares last traded at $15.67, with a volume of 696,476 shares trading hands.

Trending Headlines about Mesoblast

Here are the key news stories impacting Mesoblast this week:

• Positive Sentiment: Ryoncil revenue increased 44%. Mesoblast reported a 44% year-over-year increase in net revenue for the first quarter of fiscal 2027, led by stronger Ryoncil sales. Continued uptake could support a more favorable valuation for the company’s commercial-stage business. Mesoblast Stock Jumps on Ryoncil Sales and Lower Cash Burn
• Positive Sentiment: Cash burn fell sharply. The quarterly update showed materially lower cash spending, improving Mesoblast’s financial outlook and potentially extending its cash runway. This was a major reason investors responded favorably to the report. Mesoblast Quarterly Activity Report
• Positive Sentiment: Investors are reassessing Ryoncil’s commercial potential. Coverage highlighted the possibility that sustained prescription growth and revenue expansion could change the investment case for Mesoblast, helping drive heavy trading volume and a broad rally in the stock. Ryoncil Growth Could Change the Case for Mesoblast Stock
• Neutral Sentiment: Mesoblast’s move also occurred within a wider advance in healthcare and biotechnology shares, so sector-wide risk appetite may have amplified the company-specific reaction. Healthcare Stocks Rise
• Negative Sentiment: Mesoblast remains an early commercial-stage biotechnology company with continuing execution, profitability and regulatory risks. The rally could remain volatile if Ryoncil growth slows or quarterly cash use increases again.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Weiss Ratings upgraded Mesoblast from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, October 9th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Mesoblast in a research note on Thursday, September 24th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $39.00 target price (up from $35.00) on shares of Mesoblast in a report on Thursday, August 27th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $39.00.

Mesoblast Price Performance

The company has a current ratio of 2.43, a quick ratio of 2.09 and a debt-to-equity ratio of 0.19. The business's fifty day moving average is $14.98 and its 200-day moving average is $15.45.

Mesoblast (NASDAQ:MESO - Get Free Report) last released its earnings results on Friday, July 31st. The company reported ($0.07) earnings per share for the quarter. The business had revenue of $34.45 million for the quarter. On average, equities research analysts anticipate that Mesoblast Limited will post -0.05 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in Mesoblast in the 3rd quarter valued at about $39,000. China Universal Asset Management Co. Ltd. lifted its holdings in Mesoblast by 15.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,566 shares of the company's stock valued at $142,000 after purchasing an additional 1,247 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Mesoblast by 14.1% during the second quarter. GAMMA Investing LLC now owns 7,413 shares of the company's stock valued at $100,000 after purchasing an additional 916 shares during the last quarter. Bank of America Corp DE lifted its holdings in Mesoblast by 608.4% during the first quarter. Bank of America Corp DE now owns 100,004 shares of the company's stock valued at $1,538,000 after purchasing an additional 85,888 shares during the last quarter. Finally, Royal Bank of Canada boosted its position in Mesoblast by 22.5% during the first quarter. Royal Bank of Canada now owns 26,266 shares of the company's stock worth $404,000 after purchasing an additional 4,827 shares during the period. Institutional investors own 1.43% of the company's stock.

Mesoblast Company Profile

Mesoblast Limited is an Australia-based biotechnology company focused on developing and commercializing regenerative medicines made from specialized allogeneic mesenchymal lineage cells. The company's platform is designed to produce “off-the-shelf” cellular therapies intended to address inflammation, tissue damage and impaired healing without requiring cells to be collected from each individual patient.

Mesoblast's lead product, remestemcel-L, is marketed in the United States as RYONCIL.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.